Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.32 |
| ▸ | RXRA | P19793 | 6/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150930 | 0.94 | PRCP (0.39) | PRCPCHEK2 | |
| SCHEMBL10150929 | 0.94 | PRCP (0.39) | PRCPCHEK2 | |
| SCHEMBL12598682 | 0.93 | HCRTR1 (0.39) | — | |
| SCHEMBL10121598 | 0.91 | GABRA1 (0.32) | PRCPCHEK2 | |
| SCHEMBL22361497 | 0.88 | PRCP (0.31) | PRCPCHEK2 | |
| SCHEMBL15700801 | 0.86 | GPR119 (0.34) | NR1H2RXRANR1H3GPR119ACACB | |
| SCHEMBL10121596 | 0.86 | PRCP (0.36) | PRCPCHEK2 | |
| SCHEMBL10121589 | 0.86 | PRCP (0.36) | PRCPCHEK2 | |
| SCHEMBL22361521 | 0.86 | CHEK2 (0.36) | PRCPCHEK2 | |
| SCHEMBL10150951 | 0.86 | PRCP (0.41) | PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | PRCP 1337/4885NR1H2 1014/4885RXRA 3244/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | PRCP 1337/4885NR1H2 1014/4885RXRA 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.